(6)
Here’s why Alzamend Neuro (Nasdaq: ALZN) deserves your attention:
🧪 Breakthrough Science
Alzamend has teamed up with Massachusetts General Hospital to run five Phase II clinical trials targeting critical conditions
like Alzheimer’s, bipolar disorder (BD), major depressive disorder (MDD), and PTSD—which affect over 43 million Americans. (1)(6)(7)(8)
💡 Their lead candidate, AL001, aims to deliver the benefits of lithium therapy while avoiding its common side effects, with a 20% lower
daily dosage. This could change how lithium is used in treatment, offering a safer alternative for patients suffering from Alzheimer’s, BD, MDD, and PTSD. (1)(6)(7)
The exciting part is that AL001 has shown great promise in clinical trials so far. The results have demonstrated that it could provide better safety for patients with fewer risks associated with traditional lithium
treatments. For example, it reduces the need for regular blood monitoring, a significant advantage for patients undergoing long-term care. With its potential to disrupt the lithium market, AL001 is drawing a lot of attention as it moves one step closer to approval. (1)(6)(7)
🧬 Revolutionizing Alzheimer’s Treatment
Their second candidate, ALZN002,
takes a novel approach to Alzheimer’s, activating the body’s immune system to fight the disease by targeting and removing harmful brain plaques. This could lead to long-lasting effects and improved quality of life for patients suffering from this devastating condition. Current Alzheimer’s treatments provide limited relief, and ALZN002 could be the breakthrough patients and families have been waiting for. (1)(6)(7)
The company’s active immunotherapy approach with ALZN002 is particularly interesting. Unlike many treatments that only slow the progression of Alzheimer’s, ALZN002 has the potential to train the body’s immune system to actively fight the disease. This innovative strategy could revolutionize the way Alzheimer’s is treated, offering patients hope for long-term improvement
rather than temporary relief. (1)(6)(7)
